Medidata Medidata

COVID-19 and Clinical Trials: The Medidata Perspective

COVID-19 and Clinical Trials: The Medidata Perspective

Release 5.0

As the global impact of COVID-19 increases, Medidata is continuously analyzing its effect on patient study enrollment, the response by world regulatory bodies and which Medidata’s solutions can help address your COVID 19-related challenges. Read our latest report.

The Impact of COVID-19 on Clinical Trial Sites

Read the Results of a Global Survey Performed by Medidata.

COVID-19 and Clinical Trials: The Medidata Perspective

Release 4.0

As the global impact of COVID-19 increases, Medidata is continuously analyzing its effect on patient study enrollment, the response by world regulatory bodies and which Medidata’s solutions can help address your COVID 19-related challenges. Read our latest report.

COVID-19 and Clinical Trials: The Medidata Perspective

Release 3.0

As the global impact of COVID-19 increases, Medidata is continuously analyzing its effect on patient study enrollment, the response by world regulatory bodies and which Medidata’s solutions can help address your COVID 19-related challenges. Read our latest report.

COVID-19 and Clinical Trials: The Medidata Perspective

Release 2.0

 

As the global impact of COVID-19 increases, Medidata is continuously analyzing its effect on patient study enrollment, the response by world regulatory bodies and which Medidata’s solutions can help address your COVID 19-related challenges. Read our latest report.

COVID-19 and Clinical Trials:

The Medidata Perspective

Introduction

As COVID-19 has spread, we have been monitoring its global impact on clinical trials. We see the profound impact on our industry, both at a global level but also at the site level. Understanding what is happening on the ground is critical to define a path forward. Sharing this data is an important step, but it’s a first step. We will continue to publish updated analyses on overall industry trends throughout this pandemic and beyond.